Chagas Disease (American Trypanosomiasis) Market

Global Chagas Disease Market Size ( 2024 to 2029)

The Chagas disease market is estimated to be USD 2.63 billion in 2024 and is anticipated to reach USD 4.97 billion by 2029, with a CAGR of 12.8 during the forecast period.

Current Scenario of the Chagas Disease Market

The Chagas disease is an infectious disease caused by a protozoan parasite known as Trypanosoma cruzi. The neglect of tropical and socially determined diseases results in complex health problems. The late diagnosis and incomplete treatment can make the infection into a life-threatening condition. The Chagas disease market has witnessed considerable growth in the past years and is anticipated to grow significantly during the forecast period. According to the World Health Organization, about 6 to 7 million people worldwide are estimated to be infected by Chagas disease, which leads to approximately 12,000 deaths every year. The Chagas disease is majorly found in the endemic areas of 21 continental Latin American countries, which states that approximately 75 million people are at risk of infection. The prevalence of the Chagas disease, especially in Latin America, is a significant factor contributing to the market growth.

MARKET DRIVERS

Various factors, such as population mobility and the growing adoption of urbanization, are enhancing the transformation of the illness from rural to urban areas, contributing to the expansion of the global Chagas disease market.

For Instance, the Chagas disease is more frequently observed in the United States, Canada, most of the European region, and some nations of Africa and the Middle East. As 75 million people are at risk of infection, Chagas disease continues to be a severe threat to public health, which drives market growth. The growing government supports initiatives to create more awareness among the people regarding the effects of neglecting tropical diseases, boosting market growth opportunities. For Instance, the WHO started a campaign to raise awareness among the people, especially in Latin America, on April 14th, 2022. April 14th is designated as the Chagas Disease Day every year. These government and public organizations' support initiatives will influence the market growth.

The growing research and developmental activities for developing novel medications associated with high safety and efficacy will provide market growth opportunities. The increasing technological advancements propel the research activities, contributing to expanded market growth. The rising funding by public and private organizations for Chagas disease research will positively impact the market expansion.

MARKET RESTRAINTS

The primary factor hampering the market growth is the presence of limited diagnostic tests, which means that most patients still need to receive a diagnosis, leading to a lower treatment rate. The need for more knowledge and awareness among the people, especially in rural areas, limits market growth opportunities. The limited availability of treatment options with a restricted number of drugs approved for treatment is hindering market revenue growth. The presence of stringent regulations regarding the approval of therapeutics for the treatment owing to complexity and increased expenditure will impede the growth of the Chagas disease market. The unsatisfied results in the R&D activities and strict regulatory framework will restrict the investors from funding, negatively impacting the market growth. The side effects involved with the medications may influence negatively on the people regarding the treatment, which restrains the market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Chagas Disease Market Analysis By Treatment Type​​

The antiparasitic treatment segment dominated the Chagas disease market revenue with a prominent market share owing to the increased prevalence of Chagas disease worldwide. Antiparasitic treatment involves drugs that target the parasites causing Chagas disease, boosting the segment growth. The two crucial drugs approved for treating Chagas disease, benznidazole, and nifurtimox, which belong to this segment, enhance the growth opportunities. Antiparasitic treatment is the primary form of treatment as it directly targets the cause of disease, contributing to the market growth rate.

The symptomatic treatment segment is expected to grow considerably in the coming years. The increasing demand for drugs that manage and treat symptoms is propelling the segment's growth.

Global Chagas Disease Market Analysis By Drug Type​​​​​

The benznidazole segment held the most significant global market share and is anticipated to dominate during the forecast period. Benznidazole is mostly adopted among health professionals due to its high efficacy over the decades, propelling the. The drug is highly effective during the early stage of Chagas disease as it inhibits the replication of Trypanosoma cruzi, which causes the disease. This is enhancing the segment revenue growth. The increasing awareness among the people and the expanding healthcare industry are escalating the demand for drugs, accelerating market growth.

The nifurtimox segment is expected to increase during the forecast period. The drug's availability and various benefits, such as high efficacy and safety, are enhancing its adoption, which leads to substantial market growth.  

Global Chagas Disease Market Analysis By Distribution Channel​​

The retail pharmacies segment is dominated by notable growth and is anticipated to grow significantly during the forecast period. Retail pharmacies are gaining traction as they are accessible to patients for a wide range of medications, which is fueling the market growth in this segment. Retail pharmacies have a vast distribution network, and collaborations with industrial distribution networks propel the segment's growth rate. The increasing availability of drugs at retail pharmacies and the growing prevalence of Chagas disease are augmenting the segment growth.

The online pharmacies segment is projected to grow significantly, with the highest CAGR during the forecast period due to the increasing adoption of digital platforms for shopping among people. Online pharmacies are convenient and provide accessibility to various brands of medications, and ease of delivery is expected to create growth opportunities during the forecast period.

REGIONAL ANALYSIS

The North American region dominates the global Chagas disease market revenue with notable market share owing to the favorable government regulations and the rising prevalence of Chagas disease. According to the data provided by the CDC, Chagas disease is estimated to affect 300,000 people in the United States. The well-established infrastructure and growing healthcare expenditure across the region propel market growth. The approval of the drugs by the U.S. Food and Drug Administration is escalating the demand for therapeutic drugs, which positively influences the market growth rate in the United States.

The Asia Pacific region is estimated to have a rapid growth rate in the coming years. Rapid industrialization and growing urbanization are enhancing the healthcare industry's market revenue. The rising disposable incomes of the people are influencing them to invest in quality healthcare, which is encouraging the government to focus on improving the region's healthcare infrastructure, contributing to regional market growth.

The European region is estimated to grow considerably during the forecast period. The presence of well-established healthcare infrastructure and the pharmaceutical industry is positively influencing regional market growth. The favorable regulatory network in the region is enhancing product launches across the region, leading to market revenue growth.

Key Market Players

Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Novartis Pharmaceuticals, Chimerix, Inc, KaloBios Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Maprimed, F. Hoffmann-La Roche Ltd are some of the key market players.

Recent Market Developments

• In 2024, World Chagas Disease Day will be observed on April 14th. This global healthcare event recognizes the prevalence of infectious Chagas disease among the poor populations of Latin America. The day's theme 2024 is "Tackling Chagas disease: detect early and care for life."
• In 2023, Novartis Pharmaceuticals announced the study of phase 4 clinical trials for Enalapril and Sacubitril. The study aims to compare the impact of enalapril 10mg taken twice to the impact of sacubitril 200mg taken twice along with the treatment for heart failure. Heart failure originated from Chronic Chagas cardiomyopathy.

DETAILED SEGMENTATION OF THE GLOBAL CHAGAS DISEASE MARKET INCLUDED IN THIS REPORT

This research report on the global chagas disease market has been segmented and sub-segmented based on the following categories.

By Treatment Type

• Antiparasitic Treatment
• Symptomatic Treatment

By Drug Type

• Benznidazole
• Nifurtimox

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa